Reuters: Regulatory News: U.S. FDA advisers back Pfizer arthritis drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

U.S. FDA advisers back Pfizer arthritis drug May 9th 2012, 18:49 WASHINGTON | Wed May 9, 2012 2:49pm EDT WASHINGTON May 9 (Reuters) - Pfizer Inc won a U.S. advisory panel's support on Wednesday for its arthritis drug, which the world's largest drugmaker hopes will give a significant boost to its product pipeline after a wave of patent expiries. A panel of outside experts to the U.S. Food and Drug Administration voted 8-2 to recommend approval of tofacitinib, meant to treat patients with rheumatoid arthritis who have not had success with at least one other drug for the disease. The FDA usually follows panel recommendations, although it is not required to do so, and a final decision is expected in August.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions